Cargando…

Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone

Detalles Bibliográficos
Autores principales:	Cheng, Chongsheng, Wang, Yani, Hu, Danjing, Zhou, Wangji, Liu, Chunlong, Tian, Xinlun, Zhang, Hongbing, Xu, Ying-Chun, Xu, Kai-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Science China Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039973/ https://www.ncbi.nlm.nih.gov/pubmed/35471686 http://dx.doi.org/10.1007/s11427-022-2102-3

Ejemplares similares

Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study
por: Cheng, Chongsheng, et al.
Publicado: (2022)

Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors
por: Chen, Zhiwei, et al.
Publicado: (2022)

Clinical and Genetic Comparison of Birt–Hogg–Dubé Syndrome (Hornstein–Knickenberg Syndrome) in Chinese: A Systemic Review of Reported Cases
por: Zhou, Wangji, et al.
Publicado: (2022)

Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
por: Hu, Siqi, et al.
Publicado: (2019)

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
por: Peng, Pai, et al.
Publicado: (2021)

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
por: Zhan, Yongzhong, et al.
Publicado: (2018)

T(FH)2 cells associate with enhanced humoral immunity to SARS‐CoV‐2 inactivated vaccine in patients with allergic rhinitis
por: Yao, Yin, et al.
Publicado: (2022)

Effects of COVID-19 infection in patients with autoimmune pulmonary alveolar proteinosis: a single-center study
por: Duan, Chuanxin, et al.
Publicado: (2023)

Vasculitis Secondary to Pulmonary Bacterial Infection: A Case Report
por: Zhou, Wangji, et al.
Publicado: (2022)

Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
por: Zhao, Wen-Man, et al.
Publicado: (2022)

The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic
por: Cui, Han, et al.
Publicado: (2021)

Vitamin D deficiency and inactivated SARS-CoV-2 vaccines
por: Wu, Chia-Chao, et al.
Publicado: (2021)

Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine
por: Meng, Ziyan, et al.
Publicado: (2022)

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
por: Cao, Yunlong, et al.
Publicado: (2021)

Humoral response to vaccination against SARS-CoV-2 in patients undergoing maintenance hemodialysis
por: Delgado Ureña, Ana, et al.
Publicado: (2023)

Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
por: Gao, Bo, et al.
Publicado: (2023)

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse
por: Westhoff, Timm H., et al.
Publicado: (2021)

Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease
por: Chen, Zhiwei, et al.
Publicado: (2022)

Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study
por: Zhang, Siliang, et al.
Publicado: (2023)

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
por: Méndez, Constanza, et al.
Publicado: (2023)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population
por: Anft, Moritz, et al.
Publicado: (2021)

Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine
por: Xu, Xingli, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
por: Füessl, Louise, et al.
Publicado: (2022)

Long‐term effects of homologous and heterologous SARS‐CoV‐2 vaccination on humoral and cellular immune responses
por: Hollstein, Moritz M., et al.
Publicado: (2022)

Relapse of minimal change disease and inactivated SARS-CoV-2 vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

In Reply: SARS-CoV-2 Vaccination Related, Pediatric Guillain-Barre Syndrome Requires the Same Management as in Adults
por: Gunawan, Pricilla Yani
Publicado: (2023)

Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity
por: Pasoto, Sandra Gofinet, et al.
Publicado: (2022)

A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
por: Wang, Ji, et al.
Publicado: (2022)

Time of day influences immune response to an inactivated vaccine against SARS-CoV-2
por: Zhang, Hui, et al.
Publicado: (2021)

Poor Response to Inactivated SARS-CoV-2 Vaccine in Patients With Chronic Liver Disease
por: Cao, Huanhuan, et al.
Publicado: (2022)

Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination
por: Aydın, Mehmet Fethullah, et al.
Publicado: (2021)

Cases of severe acute liver injury following inactivated SARS-CoV-2 vaccination.
por: Kulkarni, Anand V., et al.
Publicado: (2022)

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease
por: Zaza, Gianluigi, et al.
Publicado: (2023)

Gene mutations in sporadic lymphangioleiomyomatosis and genotype–phenotype correlation analysis
por: Huang, Jiannan, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
por: Ciampi, Ethel, et al.
Publicado: (2022)

Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies
por: Sun, Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cideaif0qpvhnb4v98vppdcept